Oncolytics Receives Nasdaq Deficiency Notice After Stock Falls Below $1

Oncolytics Biotech is a clinical-stage immunotherapy company developing pelareorep, an investigational oncolytic virus being evaluated in squamous cell anal carcinoma, colorectal cancer, and other gastrointestinal tumors. The company generates no product revenue and funds operations entirely through equity issuances. With a market capitalization of approximately $101 million, it completed a redomestication from British Columbia to Nevada in March 2026, shifting its legal domicile to the United States.

The clinical pipeline has produced genuine momentum. In April 2026, the FDA aligned with the company on the design of a pivotal randomized study for pelareorep in squamous cell anal carcinoma. A separate Phase 2 randomized study in second-line colorectal cancer, REO 033, began enrolling patients in March 2026, with preliminary tumor response data expected by year-end. Earlier data from the REO 022 study showed a 33% objective response rate and a 19.5-month median duration of response for pelareorep combined with bevacizumab and FOLFIRI in KRAS-mutant metastatic colorectal cancer.

Despite those advances, the company's financial footing has drawn scrutiny. Ernst & Young, which audited Oncolytics through fiscal year 2025, included going-concern explanatory paragraphs in its audit reports for both the year ended December 31, 2024 and the year ended December 31, 2025 — signaling that the auditor assessed meaningful doubt about the company's ability to continue operating over the following twelve months in each of those periods.